In this week’s edition of InnovationRx, we look at the FDA's new rules on Covid-19 vaccines, Novartis’s acquisition strategy, ...

According to DealPulse’s M&A database, which harnesses both AI and attorneys to digest the granular deal points of publicly announced transactions, Regulus is advised by Latham & Watkins LLP, while ...

GlobalData analysts have tipped the global market for genomic therapies to balloon to almost $90 billion by 2030, driven by ...

Entered into an agreement to be acquired by Novartis for $7.00 per share in cash, with potential to receive an additional $7.00 per share in cash through a contingent ...

Learn about April 2025’s top biotech deals, featuring major collaborations in bispecific antibodies, protein therapies, and ...

30 Apr Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million Benzinga 16:28 Wed, 30 Apr Novartis to buy US biopharma outfit Regulus for up to $1.7bn ShareCast 16:15 Wed ...

A 1955 Mercedes-Benz 300 SL Gullwing owned by John and Kimberly Word of Newport Beach was named Best in Show in the recent La ...

Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Regulus Therapeutics Inc. (NasdaqCM: RGLS) to Novartis AG. Under the terms of the proposed ...

Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion. The Swiss company will pay $7 a share in cash up-front through a ...

Novartis announced that it has entered into an agreement to acquire Regulus Therapeutics, a San Diego-based, publicly traded clinical-stage biopharmaceutical company focused on developing microRNA ...